(0.18%) 5 109.31 points
(0.15%) 38 298 points
(0.20%) 15 960 points
(-1.09%) $82.94
(4.94%) $2.02
(0.10%) $2 349.50
(0.16%) $27.58
(4.14%) $960.30
(-0.18%) $0.933
(-0.31%) $10.99
(-0.46%) $0.797
(1.74%) $93.47
@ $55.32
发出时间: 14 Feb 2024 @ 00:06
回报率: -24.70%
上一信号: Feb 13 - 22:30
上一信号:
回报率: 0.69 %
Live Chart Being Loaded With Signals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France...
Stats | |
---|---|
今日成交量 | 95 427.00 |
平均成交量 | 419 558 |
市值 | 2.04B |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $0 ) 2024-05-07 |
Last Dividend | $0.300 ( 2010-06-11 ) |
Next Dividend | $0 ( N/A ) |
P/E | 16.02 |
ATR14 | $0.0430 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Petersen Floyd F. | Sell | 500 | Common Stock |
2024-03-15 | Zhang Jack Y. | Buy | 722 046 | Common Stock |
2024-03-15 | Zhang Jack Y. | Sell | 408 721 | Common Stock |
2024-03-17 | Zhang Jack Y. | Sell | 15 768 | Common Stock |
2024-03-15 | Zhang Jack Y. | Buy | 310 930 | Common Stock |
INSIDER POWER |
---|
-2.74 |
Last 100 transactions |
Buy: 1 574 905 | Sell: 1 727 474 |
Amphastar Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $644.40M |
毛利润: | $343.97M (53.38 %) |
EPS: | $2.85 |
FY | 2023 |
营收: | $644.40M |
毛利润: | $343.97M (53.38 %) |
EPS: | $2.85 |
FY | 2022 |
营收: | $498.99M |
毛利润: | $248.86M (49.87 %) |
EPS: | $1.880 |
FY | 2021 |
营收: | $437.77M |
毛利润: | $199.74M (45.63 %) |
EPS: | $1.350 |
Financial Reports:
No articles found.
Amphastar Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.300 | 2009-06-11 |
Last Dividend | $0.300 | 2010-06-11 |
Next Dividend | $0 | N/A |
Payout Date | 2010-06-30 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.600 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.66 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.09 | |
Div. Directional Score | 7.14 | -- |
Year | Amount | Yield |
---|---|---|
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.213 | 1.500 | 5.73 | 8.60 | [0 - 0.5] |
returnOnAssetsTTM | 0.0909 | 1.200 | 6.97 | 8.36 | [0 - 0.3] |
returnOnEquityTTM | 0.232 | 1.500 | 8.53 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.17 | 0.800 | 4.14 | 3.31 | [1 - 3] |
quickRatioTTM | 1.660 | 0.800 | 4.94 | 3.95 | [0.8 - 2.5] |
cashRatioTTM | 0.641 | 1.500 | 7.55 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.392 | -1.500 | 3.46 | -5.19 | [0 - 0.6] |
interestCoverageTTM | 9.50 | 1.000 | 7.59 | 7.59 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.83 | 2.00 | 8.72 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.03 | 2.00 | 8.48 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.928 | -1.500 | 6.29 | -9.43 | [0 - 2.5] |
grossProfitMarginTTM | 0.541 | 1.000 | 4.32 | 4.32 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.294 | 1.000 | 6.12 | 6.12 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.309 | 1.000 | 9.39 | 9.39 | [0.2 - 2] |
assetTurnoverTTM | 0.426 | 0.800 | -0.494 | -0.395 | [0.5 - 2] |
Total Score | 10.19 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.33 | 1.000 | 8.65 | 0 | [1 - 100] |
returnOnEquityTTM | 0.232 | 2.50 | 9.06 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.03 | 2.00 | 8.99 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.83 | 2.00 | 8.72 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.191 | 1.500 | -2.06 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.285 | 1.000 | 5.38 | 0 | [0.1 - 0.5] |
Total Score | 4.09 |
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。